{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:30:00Z","timestamp":1774701000078,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An intensive short-term chemotherapy regimen has substantially prolonged the overall survival of Burkitt\u2019s lymphoma (BL) patients, which has been further improved by addition of rituximab. However, the inevitable development of resistance to rituximab and the toxicity of chemotherapy remain obstacles. We first prepared two BL cell lines resistant to rituximab-mediated CDC. Using a phosphorylation antibody microarray, we revealed that PI3K\/AKT pathway contained the most phosphorylated proteins\/hits, while apoptosis pathway that may be regulated by PKC displayed the greatest fold enrichment in the resistant cells. The PI3K\/AKT inhibitor IPI-145 failed to reverse the resistance. In contrast, the pan-PKC inhibitor midostaurin exhibited potent antitumor activity in both original and resistant cells, alone or in combination with rituximab. Notably, midostaurin promoted apoptosis by reducing the phosphorylation of PKC and consequently of downstream Bad, Bcl-2 and NF-\u03baB. Therefore, midostaurin improved rituximab activity by supplementing pro-apoptotic effects. In vivo, midostaurin alone powerfully prolonged the survival of mice bearing the resistant BL cells compared to rituximab alone treatments. Addition of midostaurin to rituximab led to dramatically improved survival compared to rituximab but not midostaurin monotherapy. Our findings call for further evaluation of midostaurin alone or in combination with rituximab in treating resistant BL in particular.<\/jats:p>","DOI":"10.1038\/s41419-018-1259-5","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T10:47:16Z","timestamp":1545130036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Midostaurin potentiates rituximab antitumor activity in Burkitt\u2019s lymphoma by inducing apoptosis"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiaowen","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danlei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7397-6800","authenticated-orcid":false,"given":"Weiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3109\/07357900009012197","volume":"18","author":"PC Bishop","year":"2000","unstructured":"Bishop, P. C., Rao, V. K. & Wilson, W. H. Burkitt\u2019s lymphoma: molecular pathogenesis and treatment. Cancer Invest. 18, 574\u2013583 (2000).","journal-title":"Cancer Invest."},{"key":"1259_CR2","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1200\/JCO.1994.12.10.2153","volume":"12","author":"DL Longo","year":"1994","unstructured":"Longo, D. L. et al. Diffuse small noncleaved-cell, non-Burkitt\u2019s lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J. Clin. Oncol. 12, 2153\u20132159 (1994).","journal-title":"J. Clin. Oncol."},{"key":"1259_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/oxfordjournals.annonc.a059214","volume":"6","author":"LM Jost","year":"1995","unstructured":"Jost, L. M. et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt\u2019s lymphomas in adult patients. Ann. Oncol. 6, 445\u2013451 (1995).","journal-title":"Ann. Oncol."},{"key":"1259_CR4","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","volume":"109","author":"MS Cairo","year":"2007","unstructured":"Cairo, M. S. et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109, 2736\u20132743 (2007).","journal-title":"Blood"},{"key":"1259_CR5","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","volume":"109","author":"C Patte","year":"2007","unstructured":"Patte, C. et al. Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109, 2773\u20132780 (2007).","journal-title":"Blood"},{"key":"1259_CR6","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","volume":"19","author":"EJ Lee","year":"2001","unstructured":"Lee, E. J. et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J. Clin. Oncol. 19, 4014\u20134022 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1259_CR7","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","volume":"16","author":"M Divine","year":"2005","unstructured":"Divine, M. et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann. Oncol. 16, 1928\u20131935 (2005).","journal-title":"Ann. Oncol."},{"key":"1259_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","volume":"13","author":"GM Mead","year":"2002","unstructured":"Mead, G. M. et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol. 13, 1264\u20131274 (2002).","journal-title":"Ann. Oncol."},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","volume":"112","author":"GM Mead","year":"2008","unstructured":"Mead, G. M. et al. A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial). Blood 112, 2248\u20132260 (2008).","journal-title":"Blood"},{"key":"1259_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235\u2013242 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR11","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes, J. A. et al. Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis. Ann. Oncol. 22, 1859\u20131864 (2011).","journal-title":"Ann. Oncol."},{"key":"1259_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","volume":"156","author":"G Corazzelli","year":"2012","unstructured":"Corazzelli, G. et al. RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u2018unclassifiable\u2019 highly aggressive B-cell lymphoma. Br. J. Haematol. 156, 234\u2013244 (2012).","journal-title":"Br. J. Haematol."},{"key":"1259_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.12736","volume":"165","author":"DA Rizzieri","year":"2014","unstructured":"Rizzieri, D. A. et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br. J. Haematol. 165, 102\u2013111 (2014).","journal-title":"Br. J. Haematol."},{"key":"1259_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","volume":"24","author":"T Wasterlid","year":"2013","unstructured":"Wasterlid, T. et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann. Oncol. 24, 1879\u20131886 (2013).","journal-title":"Ann. Oncol."},{"key":"1259_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.13040","volume":"167","author":"S Goldman","year":"2014","unstructured":"Goldman, S. et al. Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report. Br. J. Haematol. 167, 394\u2013401 (2014).","journal-title":"Br. J. Haematol."},{"key":"1259_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","volume":"387","author":"V Ribrag","year":"2016","unstructured":"Ribrag, V. et al. Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 387, 2402\u20132411 (2016).","journal-title":"Lancet"},{"key":"1259_CR17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","volume":"13","author":"X Zhou","year":"2008","unstructured":"Zhou, X., Hu, W. & Qin, X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13, 954\u2013966 (2008).","journal-title":"Oncologist"},{"key":"1259_CR18","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359\u20137368 (2003).","journal-title":"Oncogene"},{"key":"1259_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner, G. J. Rituximab: mechanism of action. Semin. Hematol. 47, 115\u2013123 (2010).","journal-title":"Semin. Hematol."},{"key":"1259_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754\u2013758 (2002).","journal-title":"Blood"},{"key":"1259_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","volume":"101","author":"O Manches","year":"2003","unstructured":"Manches, O. et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101, 949\u2013954 (2003).","journal-title":"Blood"},{"key":"1259_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","volume":"40","author":"Z Fishelson","year":"2003","unstructured":"Fishelson, Z. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40, 109\u2013123 (2003).","journal-title":"Mol. Immunol."},{"key":"1259_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443\u2013446 (2000).","journal-title":"Nat. Med."},{"key":"1259_CR24","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","volume":"44","author":"MJ Glennie","year":"2007","unstructured":"Glennie, M. J., French, R. R., Cragg, M. S. & Taylor, R. P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44, 3823\u20133837 (2007).","journal-title":"Mol. Immunol."},{"key":"1259_CR25","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-09-4109","volume":"70","author":"S de Haij","year":"2010","unstructured":"de Haij, S. et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 70, 3209\u20133217 (2010).","journal-title":"Cancer Res."},{"key":"1259_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccr.2010.11.012","volume":"19","author":"NS Wilson","year":"2011","unstructured":"Wilson, N. S. et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 19, 101\u2013113 (2011).","journal-title":"Cancer Cell."},{"key":"1259_CR27","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch, J. et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 119, 3523\u20133533 (2012).","journal-title":"Blood"},{"key":"1259_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ctrv.2012.10.008","volume":"39","author":"M Okroj","year":"2013","unstructured":"Okroj, M., Osterborg, A. & Blom, A. M. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat. Rev. 39, 632\u2013639 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"1259_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymeth.2013.07.027","volume":"65","author":"RP Taylor","year":"2014","unstructured":"Taylor, R. P. & Lindorfer, M. A. The role of complement in mAb-based therapies of cancer. Methods 65, 18\u201327 (2014).","journal-title":"Methods"},{"key":"1259_CR30","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1172\/JCI70972","volume":"123","author":"F Montalvao","year":"2013","unstructured":"Montalvao, F. et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123, 5098\u20135103 (2013).","journal-title":"J. Clin. Invest."},{"key":"1259_CR31","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","volume":"20","author":"DG Winkler","year":"2013","unstructured":"Winkler, D. G. et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364\u20131374 (2013).","journal-title":"Chem. Biol."},{"key":"1259_CR32","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-10-3016","volume":"71","author":"W Hu","year":"2011","unstructured":"Hu, W. et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 71, 2298\u20132307 (2011).","journal-title":"Cancer Res."},{"key":"1259_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"1259_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature16533","volume":"530","author":"Z Liu","year":"2016","unstructured":"Liu, Z. et al. Autism-like behaviours and germline transmission in transgenic monkeys overexpressing MeCP2. Nature 530, 98\u2013102 (2016).","journal-title":"Nature"},{"key":"1259_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"1259_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1259_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1532\/IJH97.07028","volume":"86","author":"A Tomita","year":"2007","unstructured":"Tomita, A. et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int. J. Hematol. 86, 49\u201357 (2007).","journal-title":"Int. J. Hematol."},{"key":"1259_CR38","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","volume":"11","author":"B Jahrsdorfer","year":"2005","unstructured":"Jahrsdorfer, B. et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin. Cancer Res. 11, 1490\u20131499 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1259_CR39","doi-asserted-by":"publisher","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","volume":"67","author":"P Macor","year":"2007","unstructured":"Macor, P. et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67, 10556\u201310563 (2007).","journal-title":"Cancer Res."},{"key":"1259_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/leu.2014.185","volume":"29","author":"P Macor","year":"2015","unstructured":"Macor, P. et al. Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia 29, 406\u2013414 (2015).","journal-title":"Leukemia"},{"key":"1259_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.23460","volume":"88","author":"TE Witzig","year":"2013","unstructured":"Witzig, T. E. et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am. J. Hematol. 88, 589\u2013593 (2013).","journal-title":"Am. J. Hematol."},{"key":"1259_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454\u2013464 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR43","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib, J. et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Engl. J. Med. 374, 2530\u20132541 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR44","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay, J. et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383\u20133389 (2001).","journal-title":"Blood"},{"key":"1259_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2017.04.012","volume":"48","author":"N Isakov","year":"2018","unstructured":"Isakov, N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin. Cancer Biol. 48, 36\u201352 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"1259_CR46","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","volume":"130","author":"AH Wei","year":"2017","unstructured":"Wei, A. H. & Tiong, I. S. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 130, 2469\u20132474 (2017).","journal-title":"Blood"},{"key":"1259_CR47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/ijc.2910520622","volume":"52","author":"KA Knox","year":"1992","unstructured":"Knox, K. A. et al. Second-messenger pathways involved in the regulation of survival in germinal-centre B cells and in Burkitt lymphoma lines. Int. J. Cancer 52, 959\u2013966 (1992).","journal-title":"Int. J. Cancer"},{"key":"1259_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1006\/cimm.1999.1549","volume":"196","author":"C Keenan","year":"1999","unstructured":"Keenan, C., Thompson, S., Knox, K. & Pears, C. Protein kinase C-alpha is essential for Ramos-BL B cell survival. Cell. Immunol. 196, 104\u2013109 (1999).","journal-title":"Cell. Immunol."},{"key":"1259_CR49","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","volume":"13","author":"S Maddipatla","year":"2007","unstructured":"Maddipatla, S., Hernandez-Ilizaliturri, F. J., Knight, J. & Czuczman, M. S. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin. Cancer Res. 13, 4556\u20134564 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1259_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1158\/0008-5472.CAN-07-5171","volume":"68","author":"E Bremer","year":"2008","unstructured":"Bremer, E. et al. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res. 68, 597\u2013604 (2008).","journal-title":"Cancer Res."},{"key":"1259_CR51","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1182\/blood-2007-02-076075","volume":"110","author":"D Daniel","year":"2007","unstructured":"Daniel, D. et al. Cooperation of the proapoptotic receptor agonist rhApo2L\/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110, 4037\u20134046 (2007).","journal-title":"Blood"},{"key":"1259_CR52","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2352-3026(15)00026-5","volume":"2","author":"CY Cheah","year":"2015","unstructured":"Cheah, C. Y. et al. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b\/2 randomised study. Lancet Haematol. 2, e166\u2013e174 (2015).","journal-title":"Lancet Haematol."},{"key":"1259_CR53","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1182\/blood-2016-09-738211","volume":"129","author":"S Bhatt","year":"2017","unstructured":"Bhatt, S. et al. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. Blood 129, 2246\u20132256 (2017).","journal-title":"Blood"},{"key":"1259_CR54","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1182\/blood-2015-04-640920","volume":"127","author":"NM Czuczman","year":"2016","unstructured":"Czuczman, N. M. et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood 127, 1128\u20131137 (2016).","journal-title":"Blood"},{"key":"1259_CR55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-015-2570-1","volume":"95","author":"AK Zoellner","year":"2016","unstructured":"Zoellner, A. K. et al. Temsirolimus acts as additive with bendamustine in aggressive lymphoma. Ann. Hematol. 95, 403\u2013407 (2016).","journal-title":"Ann. Hematol."},{"key":"1259_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.leu.2404959","volume":"22","author":"M Wang","year":"2008","unstructured":"Wang, M. et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22, 179\u2013185 (2008).","journal-title":"Leukemia"},{"key":"1259_CR57","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101\u20131110 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/2040620715622613","volume":"7","author":"L Gabellier","year":"2016","unstructured":"Gabellier, L. & Cartron, G. Obinutuzumab for relapsed or refractory indolent non-Hodgkin\u2019s lymphomas. Ther. Adv. Hematol. 7, 85\u201393 (2016).","journal-title":"Ther. Adv. Hematol."},{"key":"1259_CR59","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","volume":"12","author":"S Herter","year":"2013","unstructured":"Herter, S. et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12, 2031\u20132042 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1259_CR60","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bjh.13764","volume":"171","author":"A Awasthi","year":"2015","unstructured":"Awasthi, A. et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br. J. Haematol. 171, 763\u2013775 (2015).","journal-title":"Br. J. Haematol."},{"key":"1259_CR61","doi-asserted-by":"publisher","first-page":"113895","DOI":"10.18632\/oncotarget.23040","volume":"8","author":"A Awasthi","year":"2017","unstructured":"Awasthi, A. et al. A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget 8, 113895\u2013113909 (2017).","journal-title":"Oncotarget"},{"key":"1259_CR62","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","volume":"2","author":"RM Stone","year":"2018","unstructured":"Stone, R. M., Manley, P. W., Larson, R. A. & Capdeville, R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2, 444\u2013453 (2018).","journal-title":"Blood Adv."},{"key":"1259_CR63","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper, D. J. et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19, 1485\u20131492 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1259_CR64","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","volume":"77","author":"ES Kim","year":"2017","unstructured":"Kim, E. S. Midostaurin: first global approval. Drugs 77, 1251\u20131259 (2017).","journal-title":"Drugs"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1259-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T11:25:01Z","timestamp":1671189901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1259-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1259-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734687326.793581837","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"29 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"8"}}